Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

PURPOSE: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Oncol
المؤلفون الرئيسيون: Conlon, Kevin C., Lugli, Enrico, Welles, Hugh C., Rosenberg, Steven A., Fojo, Antonio Tito, Morris, John C., Fleisher, Thomas A., Dubois, Sigrid P., Perera, Liyanage P., Stewart, Donn M., Goldman, Carolyn K., Bryant, Bonita R., Decker, Jean M., Chen, Jing, Worthy, Tat'Yana A., Figg, William D., Peer, Cody J., Sneller, Michael C., Lane, H. Clifford, Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2015
الموضوعات:
Original Reports
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268254/
https://ncbi.nlm.nih.gov/pubmed/25403209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3329
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة